Advertisement
Organisation › Details
Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)
Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the Company's most advanced product - INTUVAX® against kidney cancer - has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST). *
Start | 2002-01-01 splitoff | |
End | 2022-06-23 renamed | |
Group | Mendus (Group) | |
Today | Mendus AB (publ) (Nasdaq Stockholm: IMMU.ST) | |
Successor | Mendus AB (publ) (Nasdaq Stockholm: IMMU.ST) | |
Industry | cancer immunotherapy (immuno-oncology, I-O) | |
Industry 2 | Intuvax® | |
Person | Rohmann, Sven (Immunicum 202011 CEO before Biotech Pharmacon 200810– VP BusDev before Novartis Pharma) | |
Person 2 | Zeilemaker, Sijme (Immunicum 201703– Director Business Development before InteRNA Technologies + to-BBB Technologies) | |
Region | Göteborg (Gothenburg) | |
Country | Sweden | |
Street | 2 Grafiska Vägen | |
City | 41263 Göteborg | |
Tel | +46-31-415052 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | B: 11 to 50 (2018-12-31) |
Currency | SEK | |
Annual sales | 184,000 (income, operating (2018) 2018-12-31) | |
Profit | -97,860,000 (2018-12-31) | |
Cash | 443,798,000 (2018-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Mendus (Group)
- [1] Immunicum AB. (10/26/21). "Press Release: Immunicum Appoints Lotta Ferm as Chief Financial Officer"....
- [2] Elicera Therapeutics AB. (3/22/21). "Press Release: Elicera Announces Appointment of ATMP Specialist Karin Hoogendoorn to the Board". Gothenburg....
- [3] Immunicum AB. (11/18/20). "Press Release: Immunicum AB and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies"....
- [4] Glycotope GmbH. (9/21/20). "Press Release: DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms". Leiden & Berlin....
- [5] Immunicum AB. (12/13/19). "Press Release: Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO"....
- [6] Apceth Biopharma GmbH. (11/16/18). "Press Release: Apceth Biopharma GmbH Manufactures DCprime’s Cell-based Cancer Vaccine for Phase II Clinical Study". Munich....
- [7] Immunicum AB. (10/16/18). "Press Release: Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel - a New and Innovative Cancer Immunotherapy [Not for US, AU, CA, et al...
- [8] Immunicum AB. (10/16/18). "Press Release: Immunicum AB (publ) Clarifies Information Regarding Directed Issue [Not for US, AU, CA, et al.]"....
- [9] Immunicum AB. (10/16/18). "Press Release: Notice of Extraordinary General Meeting in Immunicum AB (publ)"....
- [10] Immunicum AB. (9/27/18). "Press Release: Immunicum AB (publ) Announces Upcoming Presentations at Conferences in October"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top